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Abstract
Background. Despite recognized risks associated with hy-
perphosphataemia in patients with chronic kidney disease
(CKD) Stage 5 on dialysis, the achievement of target levels
of serum phosphate is poor. It is likely that this is partly
due to poor adherence by patients to their phosphate-binder
treatment regimens, which often comprise large daily tablet
burdens.
Methods. In this multicentre, open-label trial, patients
on a stable dialysis regimen were screened while receiv-
ing phosphate-binder therapy, then entered into a washout
phase. Patients with serum phosphate > 1.78 mmol/L af-
ter washout entered into the main 12-week treatment phase
(N = 367), during which they were treated to target [Kid-
ney Disease Outcomes Quality Initiative (K/DOQI)]: 1.13–
1.78 mmol/L; 3.5–5.5 mg/dL) with lanthanum carbonate
monotherapy. Efficacy variables included serum phosphate
levels and the percentage of patients with serum phos-
phate control. Safety and tolerability assessments were also
conducted.
Results. Mean serum phosphate levels were significantly
reduced following 12 weeks of lanthanum carbonate
monotherapy versus previous phosphate-binder therapy.
The mean number of phosphate-binder tablets being taken
per day at screening was 7.6, but during treatment with lan-
thanum carbonate, most patients were taking doses of up to
3000 mg/day, achievable with 3 × 1000 mg tablets per day
(maximum of 6).
Conclusion. These findings suggest that lanthanum car-
bonate monotherapy offerseffective control of serumphos-
phate and, due to a low tablet burden, may help to simplify
the management of hyperphosphataemia in patients with
CKD Stage 5.
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Introduction
Hyperphosphataemia is an established risk factor for car-
diovascular mortality, renal osteodystrophy and secondary
hyperparathyroidism in patients with chronic kidney dis-
ease (CKD) Stage 5 on dialysis, and the need for adequate
control of serum phosphate is well recognized [1–3]. De-
spite this, the evidence suggests that target levels of serum
phosphate are not consistently being met. Indeed, the Dial-
ysis Outcomes and Practice Patterns Study (DOPPS) re-
vealed that less than half of the patients (40.8%) achieved
the Kidney Disease Outcomes Quality Initiative (K/DOQI)
target range for serum phosphate (1.13–1.78 mmol/L; 3.5–
5.5 mg/dL) [4]. Given the demonstrated efficacy of phos-
phate binders in clinical trials [5–9], it is unlikely that the
failure to achieve targets is entirely due to a lack of avail-
ability of effective treatments. A number of other factors
may contribute to the poor achievement of serum phos-
phate targets, including lack of patient understanding of
the consequences of hyperphosphataemia, variable dietary
managementandpooradherencetophosphate-bindertreat-
ment regimens.
Poor adherence to medication is an increasingly recog-
nized problem among patients with CKD Stage 5 [10].
These patients are subject to large daily tablet burdens and
may be prescribed >10 different medications [11]. Typi-
cally, the tablet burden can be expected to be two- to three-
fold higher than the total number of prescribed medications
per day [12]. Without doubt, the cumulative effect of mul-
tiple dosing regimens can impose a confusing and possibly
overwhelming burden on a patient. In addition, patients
with CKD Stage 5 are often elderly and the condition has
been associated with an increased rate of cognitive decline
compared with individuals with preserved renal function
[13]
Phosphate-bindertherapycontributesaconsiderablepro-
portion of the daily tablet burden for patients with CKD
Stage 5, and for some binders, nine or more tablets are
required per day to treat elevated serum phosphate lev-
els in certain patients [14,15]. Furthermore, combination
phosphate-binder therapy is commonly adopted in an at-
tempttominimizecosts,avoidexcessiveelevationofserum
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calcium levels and achieve control of serum phosphate to
target levels [1]. However, this practice may be counter-
productive if it reduces the adherence of patients to their
phosphate-binder regimens as a result of increased tablet
burden or complexity of the treatment regimen.
Lanthanum carbonate (FOSRENOL
R , Shire Pharma-
ceuticals, Basingstoke, UK) is an effective non-calcium-
based phosphate binder [16,17], for which efficacy, safety
and tolerability profiles have been demonstrated in both
short- and long-term clinical studies [18–22]. Importantly,
it has proven to be effective with a relatively low daily
tablet burden, with the majority of patients requiring a sin-
gle tablet taken during each meal [20].
In this prospective, multicentre, open-label study, we
switched patients from their previous phosphate-binder
therapy(whichfrequentlyconsistedofmorethanoneagent)
tolanthanumcarbonatemonotherapy,inordertoinvestigate
the effect on serum phosphate control and dose require-
ments. Although this study was designed to assess phos-
phate control using higher doses of lanthanum carbonate in
a clinical practice setting, other data were captured, includ-
ing the tablet burden attributable to phosphate binders.
Subjects and methods
Inclusion/exclusion criteria
The study included male and female CKD Stage 5 patients
aged at least 18 years, who had received dialysis for two
consecutive months prior to the study and had a current
requirementfortreatmentofhyperphosphataemia. Females
of childbearing potential were required to have a negative
serum pregnancy test prior to entering the study.
Patients were excluded from the study if they re-
quired continued treatment with aluminium-, calcium- or
magnesium-containingcompoundsintothestudytreatment
period. Exclusion criteria also included: significantly ab-
normal laboratory values, serum transaminases [alanine
aminotransferase (ALT) and aspartate aminotransferase
(AST)] elevated to more than three times the upper limit
of normal, intact parathyroid hormone (PTH) >85 pmol/L
(800 pg/mL) or clinically significant, uncontrolled concur-
rent illness.
Study design
This was a multicentre, open-label trial carried out in
49 centres across Europe, Israel and Canada, designed
to assess whether daily doses of lanthanum carbonate >
3000 mg offer improved rates of serum phosphate control.
Patient eligibility was assessed during a screening period
of up to 1 week. A complete medical history was taken
and demographic information recorded at this point, along
with vital signs, pre-dialysis blood profile and concomitant
medications.
The study design is summarized in Figure 1. Patients re-
ceiving prior phosphate binder(s) discontinued their treat-
ment and entered a 1- to 2-week washout period. Serum
phosphate levels were reviewed after each week. Patients
whose serum phosphate levels rose above 1.78 mmol/L
were eligible to begin lanthanum carbonate treatment and
considered to be at baseline at this point. Those who did
notdemonstratethislevelofserumphosphateafter2weeks
wereexcludedfromthestudy.Patientswhowerenotreceiv-
ing any phosphate-binder treatment and had serum levels
above 1.78 mmol/L entered the treatment period immedi-
ately following the screening period.
Patients began lanthanum carbonate treatment at a to-
tal daily recommended dose of 1500 mg/day (tablets con-
taining 250, 500, 750 and 1000 mg elemental lanthanum
wereavailable).Thedailydosewasdividedequallybetween
meals, with tablets to be chewed and taken immediately af-
ter food, and could be increased by 750 mg/day each week
to achieve optimal control of serum phosphate levels, to
a maximum of 3000 mg/day by week 3 and 4500 mg/
day by week 5 (daily dose could also be decreased).
The target serum phosphate range was 1.13–1.78 mmol/L
(3.5–5.5 mg/dL), with investigators requested to aim for
the middle of this range. Once target levels were reached,
patients received stable dosage for the remainder of the
treatment period.
The primary efficacy variable was the percentage of pa-
tients with controlled serum phosphate. The primary com-
parison was the control rate at week 3, when patients could
have been titrated up to 3000 mg/day, compared with the
rate at week 5, when patients could have been titrated up to
4500 mg/day.
Patients who completed the main 12-week study were el-
igibletocontinueintoanoptional24-weekextensionphase.
Patients entering the extension phase maintained their dose
at week 12 levels but dosage could be adjusted at any time
to achieve optimal control of serum phosphate levels.
Pre-dialysis vital signs, post-dialysis weight, concomi-
tant medications and adverse events (AEs) were assessed at
baseline, weekly for treatment weeks 1–6 and at weeks 9,
12 (end of main study), 24 and 36 (end of extension phase).
For haemodialysis patients, blood samples were collected
pre-dialysis at the first dialysis session of the week. For
peritoneal dialysis patients, study visits were scheduled for
a Monday or Tuesday. Full blood profiles were conducted
and pre-dialysis plasma lanthanum levels assessed at base-
line and weeks 3, 5, 12 and 36 (partial blood profiles were
conducted at all other visits).
Fromthefullbloodprofilesconductedatscreening,base-
lineandatweeks3,5,12and36,primary(serumphosphate)
and secondary [calcium, intact PTH and calcium × phos-
phate product (Ca × P)] efficacy variables were assessed.
For all patients, serum-intact PTH was measured using a
DPC Immulite iPTH kit. Routine physical examinations
and laboratory measurements were taken. Liver function
tests were carried out, measuring ALT, AST, gamma glu-
tamyl transferase (GGT), alkaline phosphatase and biliru-
bin levels.
Adverse events were recorded from the time that in-
formed consent was signed until the end of treatment ex-
posure and for the 30 days following the last exposure to
the study medication. Treatment-emergent adverse events
(TEAEs) were defined as those that occurred during this
period and were not present prior to the first dose of study
medication, or were present prior to the first dose of study
medication but the severity increased during treatment.Lanthanum carbonate monotherapy for hyperphosphataemia 3679
Fig. 1. Study design. Note: Week 12 was the end of study visit (visit 8) for patients who did not continue into the extension phase and was the first
visit of the extension phase (visit E1) for patients who chose to continue into the extension phase. Week E3 was the end of study visit for patients who
continued into the extension phase.
A serious adverse event (SAE) was defined as any unto-
ward medical occurrence that resulted in death, was life-
threatening, required hospitalization, resulted in persistent
or significant disability/incapacity or was a congenital ab-
normality/birth defect. Investigators recorded whether they
considered AEs/SAEs to be unrelated, possibly related or
probably related to the study medication.
Patient populations
Safety population. Safety population included all patients
whoreceivedatleastonedoseofstudymedication.Screen-
ing and baseline characteristics were reported for this pop-
ulation, as well as assessments of tolerability and safety.
Intention-to-treat (ITT) population The primary efficacy
population included all patients who received at least one
dose of lanthanum carbonate and had at least one post-
baseline phosphate measurement. Primary and secondary
efficacy data were reported for this population.
Statistics
It was anticipated that at week 3 of lanthanum carbonate
treatment(maximumdose3000mg/day),∼50%ofpatients
would be controlled, and that at higher doses (maximum
dose 4500 mg, week 5), a clinically important effect would
result in 55–60% of patients being controlled. It was es-
timated that 388 patients would be needed at week 3 and
week5toprovide90%powertodetectaminimumclinically
important difference of 5% in control rates between doses,
with 5% statistical significance determined using a two-
sidedtest.Continuousvariablesweresummarizedusingthe
number of observations, number of missing observations,
mean, standard deviation (SD), 95% confidence interval
(95% CI), median, minimum and maximum. The standard
error (SE) was presented where appropriate. Categorical
data were summarized using the number of observations,
number of missing observations and percentages. Changes
from screening were analysed using the one-sample t-test.
McNemar’s test of paired proportions was used to deter-
mine differences in control rates between weeks 3 and 5.
Table 1. Primary reasons for discontinuation from the main study
Primary reason Number of patients
Adverse events/serious adverse events 37
Patient request 22
Kidney transplant 7
Death 4
Calcium–phosphate product levels violated 3
Calcium levels violated 2
Non-compliance 2
Serum phosphate levels violated 2
Lost to follow-up 1
Other 13
All statistical testing was two sided and at the 5% level
of significance. All estimates of treatment effect were pre-
sentedwithtwo-sided95%CIs.Thelastobservationcarried
forward(LOCF)analysiswasappliedforthemainstudy(to
week 12) and for patients who entered the optional exten-
sion phase (to week 36).
Results
Patient disposition
In total, 477 patients were screened, 367 of whom en-
tered the main study. Of these, 366 received treatment, 274
completed the 12-week period, while 93 withdrew. Rea-
sons for discontinuation in the main study are presented in
Table 1.
Twohundredandelevenpatientsenteredthe24-weekex-
tension phase. Of these, 210 received treatment, 159 com-
pleted the study, while 52 withdrew. The most common
reasons for discontinuation were AEs/SAEs (17 patients),
patient request (13 patients) and kidney transplant (9 pa-
tients). TEAEs resulting in withdrawal from the study were
reported for 9.5% of patients during the extension phase.
Patient demographics and other baseline characteristics
Baseline characteristics are shown in Table 2. The majority
of patients entering the main study were male, Caucasian3680 A. J. Hutchison et al.
Table 2. Baseline characteristics for all patients entering the main study
and extension phase
Characteristic Main study
n = 366
Extension
phase n = 211
Sex, n (%)
Female 115 (31.4) 57 (27.0)
Male 251 (68.6) 154 (73.0)
Ethnic origin, n (%)
Caucasian 307 (83.9) 183 (86.7)
Black 4 (1.1) 4 (1.9)
Hispanic 5 (1.4) 4 (1.9)
Asian 12 (3.3) 4 (1.9)
Other 2 (0.5) 1 (0.5)
Missinga 36 (9.8) 15 (7.1)
Age and height, mean (SD) [range]
Age (years) 59.5
(13.81)
[24–85]
57.9 (14.53)
[27–85]
Weight (kg) 73.1
(15.47)
[33–128]
74.1 (11.53)
[33–128]
aLocal legislation prevented study centres in France from recording ethnic
or racial information.
Fig. 2. Categorization of previous phosphate-binder therapy for the main
study population (ITT population).
andhadbeenondialysisfor2yearsormore[median(range)
timesincestartingdialysis,2.42(0.2–33.3)years].Approx-
imately one-sixth had received renal transplants (16.1%)
andthemostfrequentknowncausesunderlyingCKDStage
5 were diabetes (23.2%) and glomerulonephritis (21.6%).
Medication use at screening
The number of medications that patients were receiving at
the screening visit ranged from 2 to 27 per patient (mean,
10.2).
At screening, a large proportion of the ITT popula-
tion (40.7%) were receiving more than one phosphate-
binding agent. Another 57.4% were receiving monother-
apy, and 1.9% were not receiving any phosphate binder
(Figure 2). Calcium carbonate was the most commonly
used binder (60.2%), followed by sevelamer hydrochlo-
ride (55.7%), calcium acetate (11.4%) and aluminium-
based binders (10.9%). These figures demonstrate that
combination phosphate-binder use was prevalent in this pa-
tient population. The mean total daily phosphate-binder
Fig. 3. Mean (95% CI) serum phosphate levels for the ITT population
(n = 359) and patients previously treated with one (n = 204) or two
(n = 137) phosphate binders.
tablet count for the ITT population in the main study,
whether on monotherapy or combination therapy, was
7.6 tablets (range, 1–28). For patients who required one,
two or three agents the mean (range) daily tablet count
was 5.3 (1–15), 10.5 (2–28) and 13.1 (9–21) tablets,
respectively.
Phosphate levels and control rates
At screening, 34.9% of patients met the K/DOQI serum
phosphate target range, falling to 7.0% after washout. After
3 weeks of lanthanum carbonate treatment, 39.1% of pa-
tients met the K/DOQI targets, with the control rate 43.6%
atweek5.Thepercentageofpatientswithcontrolledserum
phosphate at week 5 was observed to be higher than that
at week 3, but it was not statistically significant and was
less than the predefined level of clinical importance. Forty-
eight percent of patients were controlled to K/DOQI by
week 12, and this was statistically significant (P = 0.026)
when compared with screening levels. Of those patients
whose serum phosphate was not controlled on previous
phosphate binder(s), 26.4% achieved control on lanthanum
carbonate.
At screening, when patients were still using their pre-
vious phosphate binder, the mean (95% CI) serum phos-
phate level was 1.99 (1.92, 2.06) mmol/L. During the 1- to
2-week washout period, serum phosphate levels increased
as expected, and then decreased with lanthanum carbonate
treatment.Atweek12,themean(95%CI)serumphosphate
level was 1.84 (1.78, 1.90) mmol/L. The mean reduction
from screening in serum phosphate levels after 12 weeks
(for patients with both screening and week 12 measure-
ments) on lanthanum carbonate treatment was significant
[mean (SE) change from screening, −0.13 (0.05) mmol/L;
P = 0.007 using the one-sample t-test based on the 98.1%
patients receiving phosphate binders at screening]. Fur-
thermore, mean serum phosphate levels improved with 12
weeks of lanthanum carbonate monotherapy regardless of
whether patients were previously receiving monotherapy
(1.83 versus 1.98 mmol/L) or combination binder therapy
(1.87 versus 1.97 mmol/L) (Figure 3).Lanthanum carbonate monotherapy for hyperphosphataemia 3681
Fig. 4. Distribution of lanthanum carbonate dose levels at Week 12 (ITT
population). For each dose, the proportion of patients with serum phos-
phate levels controlled to K/DOQI targets is shown by the split bar; the
number inside the ‘controlled’ bar demonstrates the percentage of patients
controlled at that particular dose.
The distribution of dose levels at week 12 and percent-
ages of patients controlled to K/DOQI targets at each dose
are shown in Figure 4. Although the tablet burden was
not recorded in this study, most patients (57.1%) were re-
ceiving doses that could be achievable with 3 tablets per
day (≤ 3000 mg/day), with the remainder on doses achiev-
able with 6 tablets per day (median dose, 3 tablets per
day).
Ofthe48%ofpatientswhoseserumphosphatelevelsfell
withinthetargetrangebyweek12,morethanthreequarters
(77.1%) were taking daily lanthanum carbonate doses of ≤
3000 mg.
Other mineral metabolism parameters
At screening, the mean (95% CI) serum total calcium level
in the main study group was 2.35 (2.33, 2.37) mmol/L.
Levels of calcium fell following washout to 2.27 (2.25,
2.29) mmol/L at baseline, but mean serum calcium rose
back to a level similar to those observed at screening with
lanthanum carbonate treatment [2.34 (2.32, 2.37) mmol/L
at week 12]. Similar observations were made in patients
taking part in the extension phase. Calcium levels cor-
rected for albumin were almost identical to total calcium
levels.
The mean (95% CI) level of Ca × P at screening
was 4.65 (4.51, 4.80) mmol2/L2. Levels increased af-
ter washout to 5.77 (5.62, 5.93) mmol2/L2 at baseline,
but then fell following commencement of lanthanum car-
bonate therapy to below those observed at screening
[4.31 (4.16, 4.47) mmol2/L2 at week 12]. A similar
change was seen in patients taking part in the extension
phase.
At screening, the mean (95% CI) intact PTH level was
27.76 (25.29, 30.23) pmol/L but increased following the
washout period to 38.63 (35.67, 41.59) pmol/L at baseline.
Oncelanthanumcarbonatetreatmentbegan,meanPTHlev-
els decreased [33.92 (31.14, 36.70) pmol/L at week 3] and
remained relatively stable throughout treatment.
Table 3. Treatment-emergent adverse events (TEAEs) with an incidence
of ≥5% in the main study (0–12 weeks) and extension phase (12–36
weeks), according to MedDRA preferred term
Number (%) of patients
MedDRA preferred term Main study,
N = 366
Extension
phase, N = 211
Vomiting 48 (13.1) 15 (7.1)
Nausea 45 (12.3) 9 (4.3)a
Diarrhoea 35 (9.6) 17 (8.1)
Abdominal pain upper 19 (5.2) 2 (0.9)a
Nasopharyngitis 24 (6.6) 23 (10.9)
Total patients with ≥1 TEAE 259 (70.8) 152 (72.0)
aValue included for completeness due to ≥5% incidence in other section
of the study.
Compliance
The tablet intake was estimated using data detailing the
amount of lanthanum carbonate dispensed, used and re-
turnedbyeachpatient.Themediancompliancewas96.5%,
suggesting that most patients adhered to their dosing regi-
mens.
Concomitant use of calcium, cinacalcet and vitamin D
supplementation
At baseline, the mean (SD) dialysate calcium concentration
was1.46(0.40)mmol/L.Fewpatientsrequiredadjustments
to dialysate calcium concentration (6.6%) or calcium sup-
plementation (7.0%; single nighttime dose). Just over half
(52.4%) of patients used a vitamin D preparation during
the main study (45.7% of whom were treated with an active
vitamin D derivative). The vitamin D schedules used were
those of the routine clinical practice at each site and varied
from occasional oral doses to intravenous administration
at each dialysis session. No patient in the main study and
one patient in the extension phase received concomitant
cinacalcet treatment.
Safety and tolerability
Lanthanum carbonate treatment was generally well toler-
ated and caused no unexpected safety concerns. The TEAE
profile was generally typical of a population with CKD
Stage 5 receiving haemodialysis (Table 3). Although in-
creasing the dose from 3000 to 4500 mg/day did not result
inastatisticallysignificantincreaseinthepercentageofpa-
tients controlled, it had no effect on the number of TEAEs
that occurred. Treatment emergent adverse events were re-
ported for 145 (72.5%) and 114 (68.7%) patients receiving
doses up to 3000 mg/day and >3000 mg/day, respectively.
In the main study and extension phase, 14.2% and 7.6%
ofpatients,respectively,reportedSAEs.Thesewereprimar-
ily infections, cardiac disorders and gastrointestinal disor-
ders.Eightdeathsoccurredduringthestudy,sevenofwhich
were considered to be unrelated to treatment. One was doc-
umented as possibly related to treatment, the most likely
cause being reported as gastrointestinal bleeding caused
by non-infectious enteritis, complicated by excessive anti-
coagulation and possible myocardial infarction.3682 A. J. Hutchison et al.
Treatment with lanthanum carbonate caused no clini-
cally noteworthy important changes (clinical importance
was determined by site investigators) in vital signs, haema-
tological parameters or markers of liver function during
the main study. Background plasma lanthanum levels were
detectable at baseline and increased slightly following lan-
thanum carbonate treatment to 0.3–0.7 ng/mL during the
main study and to 0.5–0.8 ng/mL during the extension
phase. There was no evidence of dose dependence in these
increases, and the levels are typical of those observed in
other studies of lanthanum carbonate treatment [20,22].
Discussion
The data presented here demonstrate that patients can be
treated with lanthanum carbonate monotherapy following
either combination or monotherapy with other phosphate
binders, and levels of serum phosphate are generally main-
tained or improved. There was no significant difference
between the percentage of patients who achieved serum
phosphate control at week 3 compared with week 5, when
the maximum possible doses of lanthanum carbonate were
3000mg/dayand4500mg/day,respectively.Theadditional
percentage of patients controlled on doses of 3750 and
4500 mg compared with 3000 mg was smaller than the
pre-determined threshold for clinical importance. Hence,
only a small proportion of patients benefited from increas-
ing lanthanum carbonate doses above 3000 mg, supporting
the current clinical practice of mainly utilizing doses in the
region of 2250–3000 mg/day.
According to the protocol, titration of the dose of lan-
thanumcarbonateupto4500mg/daywaspermittedinorder
to achieve control of serum phosphate to K/DOQI targets.
Surprisingly, some patients did not achieve the K/DOQI
target range for serum phosphate and yet were not titrated
up to the maximum dose of 4500 mg/day, as permitted by
andexpected according totheprotocol. Withregard todose
titration, we consider that the behaviour of the investigators
is likely to be related to their expectations for each partic-
ular patient. If one patient has achieved serum phosphate
levels that the investigator considers to be a significant im-
provement,despitenotachievingthespecifiedtargetrange,
theymayelectnottotitratefurther.Itshouldalsobeconsid-
ered that binding dietary phosphate alone cannot eradicate
hyperphosphataemia. Phosphate may be released from the
bone under the influence of PTH [24], and the patient must
adhere to their dietary restrictions and dialysis regimen if
phosphate control is to be optimal.
Themedicalhistoryanddiseasecharacteristicsofthepa-
tients enrolled in this study were typical of a dialysis pop-
ulation, but the data relating to concomitant medications
highlight the considerable tablet burden that this disease
generates. Patients were taking up to 27 different medica-
tions on entry to the study, many of which require admin-
istration more than once a day. Indeed, the tablet burden
associated with phosphate-binder therapy alone was shown
to be extensive, with between 1 and 28 tablets per day
recorded at screening in this study.
Despite demonstrated use of phosphate binders in this
population at screening, with a large proportion of patients
receiving combination therapy, approximately two-thirds
of patients (65.1%) had serum phosphate levels that were
not controlled to K/DOQI targets. Given the efficacy that
hasbeendemonstratedinclinicaltrials[5,9],itcanbespec-
ulated that this poor level of target achievement in clinical
practice may be at least partly due to suboptimal levels of
patientadherencetotheirphosphate-bindertherapy.Failure
of patients to adhere to their prescribed treatment regimens
is believed to be related to both perceptual and practical
barriers [23]. A poor understanding of what hyperphos-
phataemia is, and of the potential dangers of failing to
control it adequately, coupled with a high daily tablet bur-
den, would be expected to impact on the extent to which
patients take their phosphate binders as prescribed. Mini-
mizing the tablet burden associated with phosphate-binder
therapy may help to improve the level of patient adher-
ence to that treatment, as well as perhaps to other medica-
tions,byreducingtheoverallcomplexityofthedailydosing
regimen.
The majority (77.1%) of patients who achieved serum
phosphate control on lanthanum carbonate treatment did so
onadoseof3000mg/dayorless,whichisequivalenttoone
tablet taken during each meal (3 per day). Given that the
mean daily tablet burden attributable to phosphate-binder
therapy prior to switching to lanthanum carbonate was
7.6 tablets, switching to lanthanum carbonate monotherapy
clearly offered a reduction in average daily tablet burden in
this study.
There is a tendency in practice to combine phosphate
binders in an attempt to improve efficacy or minimize side
effects, but this may be counterproductive, as combina-
tion phosphate-binder use can add to treatment complex-
ity, which may in turn make it more difficult for patients
to adhere. The reduction in tablet burden that lanthanum
carbonate offers may therefore help to improve patient
adherence, although a study of this design does not per-
mit us to investigate this. Nevertheless, the data from this
study support the practice of stopping other phosphate-
binder therapy altogether and switching to lanthanum car-
bonate monotherapy, as tablet burden is reduced with no
loss of efficacy or undesirable changes in serum calcium
levels. Mean intact PTH levels were generally slightly
above the upper limit of the K/DOQI-recommended range
(16.5–33 pmol/L; 150–300 pg/mL) during treatment with
lanthanum carbonate.
Treatment with lanthanum carbonate was generally well
tolerated and did not generate any unexpected safety con-
cerns compared with the screening population. The high
affinity of lanthanum for phosphate ions and the low level
of absorption from the gastrointestinal tract contribute to a
minimal drug–drug interaction profile [17,25,26]
A limitation of this study was the lack of control group.
However, a previous 6-month, randomized trial, comparing
the efficacy of lanthanum carbonate with calcium carbon-
ate, has demonstrated that lanthanum carbonate is an effec-
tivephosphatebindercomparedwithstandardtherapy[19].
In conclusion, lanthanum carbonate as a monotherapy
generated a statistically significant reduction in serum
phosphatelevelscomparedwithpreviousphosphate-binder
mono- or combination therapy in this study. In more than
three quarters of patients who achieved serum phosphateLanthanum carbonate monotherapy for hyperphosphataemia 3683
control to K/DOQI targets during the main study, the dose
at week 12 was not >3000 mg/day, which equates to just
one tablet taken during each meal. These data demonstrate
that switching to lanthanum carbonate monotherapy offers
maintained or improved control of serum phosphorus with
a reduced tablet burden. This may have positive implica-
tions for the adherence of patients with CKD Stage 5 to
their phosphate-binder therapy.
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